Study to Determine the Maximum Tolerated Dose of the PARP Inhibitor CEP-9722 in Participants With Solid Tumors

NCT01311713 · clinicaltrials.gov ↗

PHASE1,PHASE2

Phase

TERMINATED

Status

45

Enrollment

INDUSTRY

Sponsor class

Conditions

Solid Tumors

Interventions

DRUG: CEP-9722

Sponsor

Teva Branded Pharmaceutical Products R&D, Inc.